We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis announced the initiation of the ASLeap trial in patients with ankylosing spondylitis , evaluating the effect of changing to a higher dose of Cosentyx in patients who do not achieve symptom remission after treatment with Cosentyx 150 mg for 16 we